Briquilimab
As of the edition of 20 October 2026, Briquilimab is an antibody: stopped in 2026; acts on KIT.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2026
- Kind
- Antibody
- Registered trials
- 12, 5 stopped early
- Disease areas
- Immune system; Blood and lymph; Inherited and neonatal; Skin and connective tissue; Cancer; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Briquilimab.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| KIT | Mast/stem cell growth factor receptor Kit | P10721 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 4 | 0 | 1 | 2 |
| Phase 2 | 8 | 1 | 4 | 3 |
| All trials | 12 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Jasper Therapeutics | Lead sponsor of trials | 2017 to now |